BACKGROUND: Indacaterol is a novel, once-daily beta(2)-agonist in development for the treatment of asthma and chronic obstructive pulmonary disease. Studies were required to determine optimal dose(s) for continuing investigation. OBJECTIVE: A dose-ranging study was undertaken to evaluate efficacy and safety of indacaterol. METHODS: A total of 436 patients with persistent asthma receiving inhaled corticosteroids were randomized to 7 days treatment with once-daily indacaterol 50, 100, 200, or 400 microg via multi-dose dry-powder inhaler (MDDPI; Certihaler), indacaterol 400 microg via single-dose dry-powder inhaler (SDDPI), or placebo. Serial 24-h spirometry was performed on days 1 and 7. Vital signs, laboratory evaluations, and adverse events were monitored. RESULTS: All doses of indacaterol increased the mean time-standardized area under the curve of forced expiratory volume in 1 s (FEV(1)) from 22 to 24 h postdose (P <or= 0.001 vs placebo) on days 1 and 7, with clinically relevant treatment-placebo differences of 240, 260, 350, 300, and 380 ml on day 1 and 230, 220, 320, 250, and 270 ml on day 7 for indacaterol 50, 100, 200, and 400 microg via MDDPI and 400 microg via SDDPI, respectively. All doses increased mean FEV(1) (P < 0.05 vs placebo) from 5 min to 24 h postdose on days 1 and 7. All doses were well tolerated. Most adverse events were mild-to-moderate in severity: most frequently reported were respiratory, thoracic, and mediastinal disorders. CONCLUSION: Once-daily dosing with indacaterol provided sustained 24-h bronchodilation in patients with moderate-to-severe asthma, with a satisfactory overall safety profile. Indacaterol 200 microg appears the optimum dose, offering the best efficacy/safety balance.

Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: A 7-day dose-ranging study / C., Laforce; M., Alexander; R., Deckelmann; Fabbri, Leonardo; Z., Aisanov; R., Cameron; R., Owen; M., Higgins. - In: ALLERGY. - ISSN 0105-4538. - STAMPA. - 63:1(2008), pp. 103-111. [10.1111/j.1398-9995.2007.01555.x]

Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: A 7-day dose-ranging study

FABBRI, Leonardo;
2008

Abstract

BACKGROUND: Indacaterol is a novel, once-daily beta(2)-agonist in development for the treatment of asthma and chronic obstructive pulmonary disease. Studies were required to determine optimal dose(s) for continuing investigation. OBJECTIVE: A dose-ranging study was undertaken to evaluate efficacy and safety of indacaterol. METHODS: A total of 436 patients with persistent asthma receiving inhaled corticosteroids were randomized to 7 days treatment with once-daily indacaterol 50, 100, 200, or 400 microg via multi-dose dry-powder inhaler (MDDPI; Certihaler), indacaterol 400 microg via single-dose dry-powder inhaler (SDDPI), or placebo. Serial 24-h spirometry was performed on days 1 and 7. Vital signs, laboratory evaluations, and adverse events were monitored. RESULTS: All doses of indacaterol increased the mean time-standardized area under the curve of forced expiratory volume in 1 s (FEV(1)) from 22 to 24 h postdose (P
2008
63
1
103
111
Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: A 7-day dose-ranging study / C., Laforce; M., Alexander; R., Deckelmann; Fabbri, Leonardo; Z., Aisanov; R., Cameron; R., Owen; M., Higgins. - In: ALLERGY. - ISSN 0105-4538. - STAMPA. - 63:1(2008), pp. 103-111. [10.1111/j.1398-9995.2007.01555.x]
C., Laforce; M., Alexander; R., Deckelmann; Fabbri, Leonardo; Z., Aisanov; R., Cameron; R., Owen; M., Higgins
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/593622
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 39
social impact